Clinical trial
A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus
NCT02689362 is registered in ClinicalTrials.gov with Eurofarma Laboratorios S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- Eurofarma Laboratorios S.A.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 8, 2017
- Completion date
- August 9, 2018
- Enrollment
- 146 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.